Moderna has climbed more than five hundred percent this year, leaving the stock sixty-one percent above the Street’s average price target and reviving memories of the twenty-fold run that peaked in August 2021. The biotech’s market value now reflects enthusiasm for a personalized cancer vaccine still in clinical trials, while its only commercial revenue comes from respiratory vaccines facing declining demand.
The revenue cliff behind the rally
At its 2022 peak Moderna booked more than eighteen billion dollars in product sales, almost entirely from its COVID vaccine. Since then that franchise has contracted sharply, and the company has spent the past three years cutting costs while the share price fell eighty-three percent. The current portfolio, two COVID boosters, a flu shot and an RSV vaccine, has not replaced the lost volume, and the newly approved European combination shot has yet to generate meaningful sales.
The catalyst that moved the needle
Investor sentiment shifted after Moderna disclosed phase 3 data showing its candidate intismeran autogene, given with Merck’s Keytruda, met recurrence-free survival and distant metastasis-free survival endpoints in melanoma. The program is now in roughly ten trials, and management says it will discuss regulatory submissions with agencies. Most of the year’s gain arrived after that announcement, suggesting the market is pricing a commercial product that does not yet exist.
Manufacturing reality versus valuation
Personalized vaccines require bespoke production for each patient, a process that is inherently slower and costlier than standard biologics. Even if regulators approve the melanoma regimen, scaling output to match the implied valuation will be a separate challenge. Analysts’ price targets, which sit well below the current quote, appear to reflect that gap between clinical promise and commercial feasibility.
What to watch next
The next inflection points are regulatory feedback on the melanoma filing and data from the remaining trials across other tumor types. Until revenue from the cancer franchise materializes, Moderna remains a respiratory-vaccine company trading at a biotech-giant multiple.